Skip to main content
Premium Trial:

Request an Annual Quote

Texas Biotechnology Records Substantial Boost in Revenue

Premium

HOUSTON--Texas Biotechnology, a company here specializing in computer-aided small-molecule drug design, has reported third-quarter results that show nearly a nine-fold increase in revenue compared to the same period last year. That's largely because of an $8.5 million license fee that came from a corporate partnership with SmithKline Beecham. In addition, operating expenses for the quarter fell compared to the same period last year.

Revenues for the third quarter were $9.7 million, compared to $1.1 million for the same period in 1996. Operating expenses for the three months ending September 30 were $5.5 million, compared to $6.9 million for the same quarter in 1996. The company attributed the decreased expenses to a reduction in R&D costs related to the completion of clinical trials for the drug Novastan.

Revenues for the nine months ending September 30 were $11.2 million, compared to $4.3 million for the same period in 1996. Net loss for the first three quarters of this year was $6.8 million, down from $16 million for the first three quarters of 1996. The company is focused on developing a new generation of therapeutics focusing on preserving the functional integrity of the human vascular system. It has also generated lead compounds for the inhibition of cell adhesion, endothelin, growth factors and programmed cell death.

Filed under

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.